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University of Southern California, Los Angeles, CA, USA, 2 GlaxoSmithKline, RTP, NC, USA OBJECTIVES: To investigate the impact of comorbid cardiovascular disease (CVD) on antidiabetic medication adherence. METHODS: Eligibility and claims data (2002) (2003) (2004) were used to identify patients ≥40 years of age with a diagnosis of type 2 diabetes concurrent with hypertension (HYPT), coronary artery disease (CAD), and/ or heart failure (HF), and at least two prescription fills for an antidiabetic medication. Medication adherence was assessed using proportion of days covered ≥0.8. Multivariable logistic regressions were used to assess CVD and other risk factors associated with nonadherence with antidiabetic medication using 2004 data. RESULTS: A total of 16,922 patients were identified. Patients with two comorbid CVD were more likely to use or be adherent with combination cardiovascular and antidiabetic medications [HYPT + CAD (79%/28%, represented as proportion of use/adherent rate), HF + CAD (88%/31%)] than those with a single comorbid CVD [HYPT (68%/21%), CAD (65%/21%), and HF (72%/21%), respectively, p < 0.0001]. The adherence rate for use of both antidiabetic and cardiovascular medications was only 24%. The major significant predictors of diabetic medication nonadherence included no fill of University of the Sciences in Philadelphia, Philadelphia, PA, USA, 2 iGuard, Inc, Princeton, NJ, USA OBJECTIVES: As individual treatment guidelines for diabetes, dyslipidemia and hypertension have evolved with more aggressive treatment targets, there may be an unintended consequence of poor medication adherence in patients having all three conditions. The study objective was to investigate how patient health beliefs affect medication adherence in patients with coexisting diabetes, dyslipidemia and hypertension. METHODS: An online survey was administered in December 2008 to iGuard. org members. Patients taking at least 1 medication for diabetes, dyslipidemia and hypertension were invited to participate in the nationwide survey (n = 2150). Survey items included demographics, the Medication Adherence Report Scale (MARS)-(score = 5-25), potential adherence barriers and adherence trade-off scenarios. Patients were assigned a dominant health belief among the three disease states based on responses to the trade-off scenarios. Medication adherence rates between diabetes and hypertension health belief groups (dyslipidemia group excluded due to small sample size) and trade-off scenario selections were compared using z-tests. RESULTS: A total of 325 patients completed the survey, 218 patients demonstrated a dominate health belief for diabetes, 81 for hypertension, 13 for dyslipidemia and 13 with no dominate health belief. In trade-off scenarios, patients consistently stated they would choose taking diabetes medications over hypertension and dyslipidemia medications. (p < 0.01) Complete adherence (MARS score = 25) with diabetes medications was higher in the diabetes health belief group (39.4%) compared to hypertension health belief group (22.2%) (p = 0.008); however there was no difference between the groups with complete adherence to hypertension (p = 0.811) or dyslipidemia (p = 0.278) medications. CONCLUSIONS: Diabetes therapy was considered the most important therapy to the majority of patients with coexisting diabetes, dyslipidemia and hypertension. However, in patients who considered hypertension therapy most important, there was significantly less adherence to diabetes medications while exhibiting similar adherence to hypertension and dyslipidemia medications. These insights could be considered by clinicians when assessing adherence in these complex patients.
PCV103 A METHODOLOGY FOR USING CLAIMS DATA FROM ELECTRONIC PRESCRIBERS TO ASSESS FIRST FILL FAILURE RATE OF ANTIHYPERTENSIVE PRESCRIPTIONS
Belletti DA 1 , Lee HY 2 , Xing S 3 , Cooke CE 4 1 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2 CareFirst BlueCross BlueShield, Baltimore, MD, USA, 3 University of Maryland School of Pharmacy, Baltimore, MD, USA, 4 PosiHealth, Inc., Ellicott City, MD, USA OBJECTIVES: Despite numerous studies on medication adherence, there is little research on the first prescription fill rate. Our study used claims data from electronic prescribers to calculate first fill failure rate for antihypertensive prescriptions. METHODS: This retrospective study combined administrative, medical and pharmacy claims data from a health plan to find the percentage of unclaimed, first fill antihypertensive prescriptions, the primary outcome. Adult members with new antihypertensive prescriptions prescribed by an electronically prescribing physician were eligible for inclusion. We allowed only prescriptions written by physicians who were electronically prescribing in order to capture antihypertensive prescriptions that would likely be adjudicated with a claim captured. Each antihypertensive prescription was assigned one outcome: paid claim (patient obtained prescription) and denied claim (unclaimed prescription). RESULTS: The cohort consisted of 14,693 new antihypertensive prescriptions prescribed by 164 electronically prescribing physicians. First fill failure rate was 15.6% for prescriptions which affected 24.3% of patients. We examined the accuracy of this new methodology by verifying the prescription rate through medical record abstraction. Chart review occurred for 183 of the 200 charts. There were 254 antihypertensives prescribed, of which 247 (97.2%) had a matching pharmacy claim. Our methodology identified 97.2% of the prescribed antihypertensives and implies that 2.8% of prescriptions would not have been identified. CONCLUSIONS: Using electronic prescribers to proxy electronic prescribing is a new method for assessing first fill rates. The intent was to identify most of the prescribed antihypertensives so that matching pharmacy claims would determine whether the prescription was obtained. With a potential error rate of 2.8% of prescriptions, this methodology appears sensitive and accurate to determine adherence to first fill prescriptions. Future research should examine the correlation between the use of electronic prescriber data and electronic prescriptions. Adherence to therapy was compared between SPC and MPC groups and measured using the National Quality Forum-endorsed proportion of days of medication coverage (PDC) metric. Multivariate regression models were used to control for baseline differences between groups such as demographic characteristics, co-morbid conditions, and health resource utilization and to estimate the association between type of treatment group and optimal adherence (PDC ≥ 0.80). RESULTS: A total of 42,460 patients [38,847 SPC, age 56.3 ± 12 (mean ± SD), 55% men; 3,613 MPC, age 54.8 ± 11.6, 62% men] were identified. The mean PDC was 0.76 and 0.70 in the first 3 months of treatment, 0.54 and 0.45 in the second 3 months, and 0.50 and 0.41 for the remaining 30 months of follow-up for the SPC and MPC groups, respectively (p < 0.01 for each time period). This observed trend in sustained higher PDC for the SPC group compared to the MPC group remained even after controlling for baseline patient characteristics. Furthermore, multivariate logistic regression indicated that SPC patients were 31% more likely to be optimally adherent to treatment than MPC patients (OR = 1.31; 95% CI: 1.27-1.35; p < 0.01). CONCLUSIONS: Medication adherence was significantly higher among patients receiving single-pill combination therapies compared to multi-pill combination therapies. The results suggest single-pill therapies may improve health outcomes in patients due to improved medication adherence. Single-pill dyslipidemia therapies, where indicated, may be an important addition to health plan drug formularies because of their improved medication adherence profile.
PCV104 AN ASSESSMENT OF ADHERENCE TO SINGLE-PILL VERSUS MULTI-PILL COMBINATION LIPID-MODIFYING THERAPIES AMONG PATIENTS WITH MIXED DYSLIPIDEMIA IN A MANAGED CARE POPULATION

PCV105 UNDERSTANDING BARRIERS TO MEDICATION ADHERENCE FOR THE
Nair KV 1 , Jan S 2 , Belletti D 3 , Doyle J 4 , Allen RR 1 , Patel J 5 1 University of Colorado, Aurora, CO, USA, 2 Horizon Blue Cross Blue Shield of New Jersey, Newark, NJ, USA, 3 Novartis Pharmaceuticals Corp., Walnutport, PA, USA, 4 Novartis, East Hanover, NJ, USA, 5 Care Management International, Marlborough, MA, USA OBJECTIVES: Although hypertension is a major risk factor for cardiovascular disease, medication adherence to hypertensive medications is low. Previous research identifying factors influencing adherence have focused primarily on broad, population-based approaches. Identifying specific barriers for an individual is more useful in designing meaningful interventions. Using customized telephonic outreach, we examined the specific barriers influencing hypertensive patients' non adherence in order to identify targeted interventions. METHODS: Sample represented members from a health plan in 2008 with ≥2 prescriptions for hypertensive medications. Non adherent members had a Medication Possession Ratio (MPR) of <80% for at least one of their hypertensive drugs. Telephone script was based on the "target" drug with the lowest MPR. Study was implemented in fall 2008. RESULTS: Response rate was 28.2% (n = 8692); 22.6% commercial and 49.8% Medicare respondents. Mean age was 63.4, 54.3% were female; mean MPR was 61% for the target drug. Majority of respondents (∼60%) had adherence levels between 60-79%. However, only 58.2% of Medicare and 60.4% of commercial respondents reported "missing a dose of medication". Primary reason was forgetfulness (61.8% Medicare; 60.8% commercial) followed by
